Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04478019 · ClinicalTrials.gov registry record · Early Phase 1
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
A Early Phase 1 study of COVID-19 and SARS-CoV-2, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 245
- Enrollment target
- 1
- Study location
NCT04478019 is a Early Phase 1 study of COVID-19 and SARS-CoV-2 that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 245 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04478019, a Early Phase 1 study of COVID-19 and SARS-CoV-2, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 245 participants
- Enrollment target
- 1
- Study location
Study Summary
Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare and other essential workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, as well as the general public to essential worker,. and thus reducing the incidence of COVID-19 in these workers.
Conditions Studied
Interventions
- DRUG 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Study Locations (1)
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2022-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04478019
The ClinicalTrials.gov registry entry for NCT04478019 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse is the first listed.
NCT04478019 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04478019 about?
NCT04478019 is a clinical study titled "SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding". Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedure...
What is the current status of trial NCT04478019?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 245 participants. The study started on 2020-07-07. Estimated completion is 2022-06-30.
What conditions does trial NCT04478019 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
What interventions are being tested in trial NCT04478019?
The interventions under investigation include: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse (DRUG).
Who is sponsoring clinical trial NCT04478019?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04478019 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.